A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples

Peking Union Medical College Hospital150 enrolled

Overview

EGFR mutations plays an essential role in EGFR-TKIs treatment. However, for some patients, tissue samples are not available. The purpose of this study is to determine whether blood sample is feasible for EGFR mutation detection.For late stage NSCLC, we hypothesis plasma sample is an alternative for detecting EGFR mutations.

Study Type

OBSERVATIONAL

Enrollment

150

Conditions

Carcinoma, Non-Small-Cell Lung

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Non-small cell lung cancer * Available plasma and pathologically confirmed tissue slices(pre-chemo and pre-radio therapy) * Informed Consent Exclusion Criteria: * N/A

Locations (1)

Peking Union Medical College Hospital

Beijing, China

Outcomes

Primary Outcomes

To determine the consistence of EGFR mutation status in paired tissue and plasma samples

Time frame: 3 months

Secondary Outcomes

To determine the EGFR mutation status in Chinese NSCLC

Time frame: 3month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.